Biomarkers Market Worth $93.8 billion | MarketsandMarkets(TM)

Compatibilidad
Ahorrar(0)
Compartir

CHICAGO, April 25, 2024 /PRNewswire/ -- Biomarkers Market [https://www.marketsandmarkets.com/Market-Reports/biomarkers-advanced-technologies-and-global-market-43.html?utm_source=Prnewswire&utm_medium=referral&utm_campaign=paidpr] in terms of revenue was estimated to be worth $57.7 billion in 2024 and is poised to reach $93.8 billion by 2029, growing at a CAGR of 10.2% from 2024 to 2029 according to a new report by MarketsandMarkets(TM).

https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg [https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg]

The growing significance of biomarkers in drug discovery and development, and the growing importance of companion diagnostics [https://www.marketsandmarkets.com/Market-Reports/companion-diagnostics-market-155571681.html?utm_source=Prnewswire&utm_medium=referral&utm_campaign=paidpr] are the major driving factors of the biomarkers market. However, high capital investments and lengthy timelines for biomarker development can hamper market growth.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=43 [https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=43&utm_source=Prnewswire&utm_medium=referral&utm_campaign=paidpr]

Browse in-depth TOC on "Biomarkers Market"

699 - Tables
53 - Figures
520 - Pages

Biomarkers Market Scope:

Report Coverage Details Market Revenue in 2024 $57.7 billion Estimated Value by 2029 $93.8 billion Growth Rate Poised to grow at a CAGR of 10.2% Market Size Available for 2022-2029 Forecast Period 2024-2029 Forecast Units Value (USD Billion) Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends Segments Covered Product & Service, Type, Research Area, Technology, Disease Indication, Application, and End User Geographies Covered North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa Report Highlights Updated financial information / product portfolio of players Key Market Opportunities Shift towards personalized medicine and precision oncology Key Market Drivers Increase in global prevalence of cancer

The consumables segment accounted for the largest share by product & service segment in the biomarkers market in 2023.

By product & service, the biomarkers market is categorized into consumables, services, and software. The consumables are further sub-segmented into assay kits, reagents & chemicals, columns & filters. The consumables accounted for the largest share of the global biomarkers market in 2023. The large share of consumables is due to the necessity for high-quality products to ensure accurate test results, coupled with the repetitive need for these consumables due to ongoing sample testing in research and clinical settings.

The safety biomarkers segment accounted for the largest share by type segment in the biomarker market in 2023.

By type, the biomarkers market is categorized into safety biomarkers, efficacy biomarkers, and validation biomarkers. The efficacy biomarkers are sub segmented into predictive biomarkers, surrogate biomarkers, pharmacodynamics biomarkers, and prognostic biomarkers. The safety biomarkers segment is expected to grow at the highest CAGR during the forecast period. This can be attributed to their importance in ensuring the safety of pharmaceuticals and healthcare interventions. Safety biomarkers are specifically designed to assess the potential adverse effects, toxicity levels, and safety profiles of drugs and treatments during clinical trials [https://www.marketsandmarkets.com/Market-Reports/clinical-trials-market-405.html?utm_source=Prnewswire&utm_medium=referral&utm_campaign=paidpr] and post-marketing surveillance.

The NGS segment is expected to grow at a higher rate during the forecast period.

Based on technology, the biomarkers market has been segmented into immunoassays, NGS, PCR, mass spectrometry [https://www.marketsandmarkets.com/Market-Reports/mass-spectrometry-market-437.html?utm_source=Prnewswire&utm_medium=referral&utm_campaign=paidpr], chromatography, and other technologies. The immunoassay technology is sub segmented into ELISA, western blot, and protein microarray. In 2023, the immunoassays segment accounted for the largest share of the biomarkers market, and the NGS segment is expected to grow at a higher growth rate during the forecast period of 2024-2029. The immunoassay segment's growth is driven by its extensive use in clinical settings for diagnosing diseases, monitoring treatment effectiveness, and predicting patient outcomes.

The cancer segment accounted for the largest share of the disease indication segment in the biomarkers market in 2023.

Based on the disease indication, the biomarkers market is segmented into cancer, infectious diseases [https://www.marketsandmarkets.com/Market-Reports/infectious-disease-diagnostics-market-116764589.html?utm_source=Prnewswire&utm_medium=referral&utm_campaign=paidpr], immunological disorders, neurological disorders, cardiovascular disorders, and other disease indications. In 2023, cancer accounted for the largest share of the biomarkers market. The expansion of the cancer biomarkers market is fueled by a surge in research funding dedicated to the rising personalized drug products for cancer treatment.

The North America region accounted for the largest share of the biomarkers market in 2023.

The biomarkers market is segmented into North America, Europe, Asia Pacific (APAC), Latin America (LATAM), the Middle East, and Africa. The North America region is witnessing increasing investments and research activities in the field of drug discovery. The need for advanced therapies due to the increased prevalence rate of cancer has contributed to the growth of the biomarkers market.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=43 [https://www.marketsandmarkets.com/requestsampleNew.asp?id=43&utm_source=Prnewswire&utm_medium=referral&utm_campaign=paidpr]

Biomarkers Market Dynamics:

Drivers:

    1. Increase in global prevalence of cancer

Restraints:

    1. Disease complexity and heterogeneity

Opportunities:

    1. Shift towards personalized medicine and precision oncology

Challenge:

    1. Challenges associated with integration of complex data sets

Key Market Players of Biomarkers Industry:

Key players in the biomarkers market F. Hoffmann-La Roche Ltd (Switzerland), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Abbott (US), QIAGEN (Netherlands), Revvity (US), Laboratory Corporation of America Holdings (US), Charles River Laboratories (US), Bio-Rad Laboratories, Inc. (US), Eurofins Scientific (Luxembourg), BIOMÉRIEUX (France), Agilent Technologies, Inc. (US), JSR Corporation (Japan), Quanterix (US), MESO SCALE DIAGNOSTICS, LLC. (US), EKF Diagnostics (UK), Celerion (US), Standard BioTools (US), Sebia (France), BioAgilytix Labs (US), StressMarq Biosciences Inc. (Canada), NorthEast BioAnalytical Laboratories LLC (US), Signosis, Inc. (US), Serimmune (US), TheraIndx Lifesciences Pvt. Ltd. (India), Synexa Life Sciences BV (Netherlands), Diatech Pharmacogenetics (Italy), Singulex, Inc. (US), R-Biopharm AG (Germany), and Proteome Sciences (UK).

The primary interviews conducted for this report can be categorized as follows:

    --  By Respondent: Supply Side- 70% and Demand Side 30%
    --  By Designation: C-level Executives - 55%, Director-level - 20%, and
        Others - 25%
    --  By Region: North America -45%, Europe -20%, Asia-Pacific -20%, Latin
        America -10%, Middle East -3%, and Africa-2%

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=43 [https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=43&utm_source=Prnewswire&utm_medium=referral&utm_campaign=paidpr]

Recent Developments of Biomarkers Industry:

    --  In January 2024, Quibim and Merck KGaA partnered to develop diagnostic
        tools to develop the next generation of precision medicine technology
        targeting a wide range of cancers
    --  In October 2023, Quanterix Corporation, a company specializing in
        ultrasensitive biomarker detection, has announced a new agreement with
        Johnson & Johnson's Janssen Sciences Ireland UC to advance blood-based
        Alzheimer's disease detection. The agreement grants Quanterix
        non-exclusive rights to J&J's p-Tau 217 antibodies and assay designs,
        enabling the development of a potential Laboratory Developed Test (LDT)
        for Alzheimer's Disease (AD) diagnosis and clinical research
    --  In February 2023, F. Hoffmann-La Roche Ltd launched two new antibodies
        to understand a patient's brain tumor mutation status in the IDH1 and
        ATRX genes that help in more informed clinical decisions and may improve
        patient outcomes

Biomarkers Market - Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall biomarkers market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

    --  Analysis of key drivers (Growing significance of biomarkers in drug
        discovery and development, Growing importance of companion diagnostics,
        Increase in global prevalence of cancer, Growing importance of
        biomarkers for rare conditions, Increase in funds and grants for
        biomarker research, Advancement in omics technologies and continuous
        product innovations), restraints (High capital investments and lengthy
        timelines for biomarker development, Disease complexity, and
        heterogeneity), opportunities (Shift towards personalized medicine and
        precision oncology, Enhanced collaboration among healthcare providers
        and key industry players, Emerging economies), and challenges
        (Challenges associated with quantification and validation of biomarkers,
        Challenges associated integration of complex data sets, Technical issues
        related to sample collection and storage) influencing the growth of the
        market.
    --  Product Development/Innovation: Detailed insights on newly launched
        products/services of the biomarkers market
    --  Market Development: Comprehensive information about lucrative markets -
        the report analyses the market across varied regions.
    --  Market Diversification: Exhaustive information about new
        products/services, untapped geographies, recent developments, and
        investments in the biomarkers market
    --  Competitive Assessment: F. Hoffmann-La Roche Ltd (Switzerland), Merck
        KGaA (Germany), Thermo Fisher Scientific Inc. (US), Abbott (US), QIAGEN
        (Netherlands), Revvity (US), Laboratory Corporation of America Holdings
        (US), Charles River Laboratories (US), Bio-Rad Laboratories, Inc. (US),
        Eurofins Scientific (Luxembourg), BIOMÉRIEUX (France), Agilent
        Technologies, Inc. (US), JSR Corporation (Japan), Quanterix (US), MESO
        SCALE DIAGNOSTICS, LLC. (US), EKF Diagnostics (UK), Celerion (US),
        Standard BioTools (US), Sebia (France), BioAgilytix Labs (US),
        StressMarq Biosciences Inc. (Canada), NorthEast BioAnalytical
        Laboratories LLC (US), Signosis, Inc. (US), Serimmune (US), TheraIndx
        Lifesciences Pvt. Ltd. (India), Synexa Life Sciences BV (Netherlands),
        Diatech Pharmacogenetics (Italy), Singulex, Inc. (US), R-Biopharm AG
        (Germany), and Proteome Sciences (UK) among others in the market.

Related Reports:

Companion Diagnostics Market [https://www.marketsandmarkets.com/Market-Reports/companion-diagnostics-market-155571681.html?utm_source=Prnewswire&utm_medium=referral&utm_campaign=paidpr] - Global Forecasts to 2029

Cardiac Marker Testing Market [https://www.marketsandmarkets.com/Market-Reports/cardiac-marker-market-64885447.html?utm_source=Prnewswire&utm_medium=referral&utm_campaign=paidpr] - Global Forecasts to 2028

Drug Discovery Services Market [https://www.marketsandmarkets.com/Market-Reports/drug-discovery-services-market-138732129.html?utm_source=Prnewswire&utm_medium=referral&utm_campaign=paidpr] - Global Forecasts to 2028

Cancer Profiling Market [https://www.marketsandmarkets.com/Market-Reports/cancer-tumor-profiling-market-1250.html?utm_source=Prnewswire&utm_medium=referral&utm_campaign=paidpr]- Global Forecasts to 2027

Cancer Biomarkers Market [https://www.marketsandmarkets.com/Market-Reports/oncology-biomarkers-202.html?utm_source=Prnewswire&utm_medium=referral&utm_campaign=paidpr] - Global Forecasts to 2026

About MarketsandMarkets(TM):

MarketsandMarkets(TM) has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets(TM) is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore(TM) (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets(TM).com [http://www.marketsandmarkets.com/] or follow us on Twitter [https://twitter.com/marketsmarkets], LinkedIn [https://www.linkedin.com/company/marketsandmarkets/about/] and Facebook [https://www.facebook.com/MarketsandMarkets].

Contact:
Mr. Aashish Mehra
MarketsandMarkets(TM) INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com [mailto:sales@marketsandmarkets.com]
Research Insights: https://www.marketsandmarkets.com/ResearchInsight/biomarkers-advanced-technologies-and-global-market.asp [https://www.marketsandmarkets.com/ResearchInsight/biomarkers-advanced-technologies-and-global-market.asp]
Visit Our Website: https://www.marketsandmarkets.com/ [https://www.marketsandmarkets.com/]
Content Source: https://www.marketsandmarkets.com/PressReleases/biomarker.asp [https://www.marketsandmarkets.com/PressReleases/biomarker.asp]

Logo: https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg [https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jp]

View original content:https://www.prnewswire.co.uk/news-releases/biomarkers-market-worth-93-8-billion--marketsandmarkets-302127077.html [https://www.prnewswire.co.uk/news-releases/biomarkers-market-worth-93-8-billion--marketsandmarkets-302127077.html]

Photo: https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg MarketsandMarkets
Imágenes (1)
Detalles de contacto
PRNewswire